AChillese woma n came to the otolaryngo iogy departm ent with a comp lai nt ofa longstanding pro gressive left heating loss and intractable tinnir us . A fi nding of asymmetry Oll senso rineural hea ring loss and auditory brainstem respo nse testing pro vid ed evidanee of a retrocochlear lesion Oll the left side . Camputed tomograpliy and magnetic reso nance imaging detected a tum or in the left int erna l auditc ry ca nal (IAC) . ln addition to these radi ologicfeatures , our suspicio n of the possibility of all IAC lipoma was rai sed by the obse rva tion ofmu ltip le lipomas ove r the pati ent 's trun k and limb s. Th e pa tient underwent a complete tum or resection via the tra nslabyrintliiue app roach . Pathology co nfi rme d the diag uo sis of an lAC lipoma . Altho ugh lI'e lI'ere 1I0t ablc to p re serve the hearing iII her left ear, the po tient lI'as sa tisfi ed tha t lI' e luid re lieved her co nstant tinnitus. III this article , lI' e revie w the particulars of this case and discuss the clinical, radiologic, and pathologi c [e at ure s of IAC lipomas .
Abstract
AChillese woma n came to the otolaryngo iogy departm ent with a comp lai nt ofa longstanding pro gressive left heating loss and intractable tinnir us . A fi nding of asymmetry Oll senso rineural hea ring loss and auditory brainstem respo nse testing pro vid ed evidanee of a retrocochlear lesion Oll the left side . Camputed tomograpliy and magnetic reso nance imaging detected a tum or in the left int erna l auditc ry ca nal (IAC) . ln addition to these radi ologicfeatures , our suspicio n of the possibility of all IAC lipoma was rai sed by the obse rva tion ofmu ltip le lipomas ove r the pati ent 's trun k and limb s. Th e pa tient underwent a complete tum or resection via the tra nslabyrintliiue app roach . Pathology co nfi rme d the diag uo sis of an lAC lipoma . Altho ugh lI'e lI'ere 1I0t ablc to p re serve the hearing iII her left ear, the po tient lI'as sa tisfi ed tha t lI' e luid re lieved her co nstant tinnitus. III this article , lI' e revie w the particulars of this case and discuss the clinical, radiologic, and pathologi c [e at ure s of IAC lipomas .
Introd uction
Lipomas of the internai auditc ry ca na l (lA C) are rare, beni gn neoplasm s that occ ur primarily in white men dur ing the third to fift h decade s of life. To our know ledge, the first reported case of an lAC lipoma was seen on autopsy by Klob in 1859. 1 Until now, only 84 cases of ei ther lAC OI' cerebellopontine ang le (CPA) lipoma have been repo rted in the English-lan gua ge literature . ' We descr ibe a new case of lAC lipoma in a pati ent who a1so had multiple lipomas over the tru nk and extremit ies. We also discuss the clinical sy mptoms, radiolo gic characteristics, and patholo gic features of lA C lipom as, along with treatmen t options and surgical complications. From Case report A 4 1-year-old Chin ese woman reported that she had been ex periencing a progressive left hearin g loss with inte rmittent tinn itus for man y years, T he tinn itus had becom e constant and intrac tab le despite medical treatm ent during the pre vious 6 month s. An otoscopic exami natio n revea led no abnormalities. A ge neral physica l exami nation, however, revealed that the patient had man y ela stic and nodular subcutaneous lesions over her left fore arm, abdomen, and buttocks. She also had man y pigmen ted nev i ove r her forearm.
An audiogram detected a left sensorine ural hearing loss. Th e patienr' s pure-tone ave rage was ap proximately 50 dB, her speec h recepti on threshold was about 40 dB, and her speec h discri minatio n score was 94 %. Electronystagm ography and ca loric testin g fo und no unilateral weak ness OI' dire ctio na l preponderance. Her aud itory brai nstern res ponse show ed a 0.26-msec interaur al wave V de lay on the left. A finding of asymme try on se nsorineural hearin g loss and auditory brainstern response testing provid ed evide nce of a retrococ hlea r lesion on the left side.
Hig h-resolution computed tomograph y (CT) detected a lesion in the left lAC with a signal of -29 to -109 Hou nsfield units ( figure 1A ).T I-weighted mag netic resonance imaging (MRl) dem on strated a l Ox S-mm lesion in the same location (figure 1B). On T l -weighted ax ial and coronal MRl, the lesion emitted a hyperinten se signal, Con versely, on T2-weight ed coro nal MR l, it emi tted a hypointense signa l (fig ure IC). After gado linium administration , there was no significant contrast enha nce ment (figure I D). Th ese findings are compatible with the pre senee of a lipoma.
Th e patient underwent a resecti on of the lAC tum or via a translabyrinthine approach. During surge ry, we noted that the so ft, yellowish tumor ap peared to ar ise fro m the inferi or vesti bular nerve and adhere tightl y to the facial nerve. We removed the 8 x 8 x 4-mm tum or with a sharp dissection, but we had to sacrifice the auditc ry nerve to do so. Later, we also rem oved a 3.0 x 2.7 x l A-c m soft tissue mass fro m the left fore arm. Following surgery, the patient experienced vertigo , cerebrospinal fluid leakage, and facial weakness (House-Brackmann grade IV). Re-exploration with fat obliteration was performed. Once the leak was corrected, the verti go subsided. On histolo gy, the lAe tumor showed nerv e tissue with fatt y infiltration (figure 2), while the fore arm tumor showed an angiolipoma. At the 6-month follo wup , the patient 's tinnitu s had disappeared, her facial weakne ss had improved to Hou se-Brackmann grade II status, and a repeat MRI detected no evidence of tumor recurrence.
Discussion
Intra cranial lipomas are very rare, accounting for only 0.1% of all cerebral tumors.' Lipom as also make up less than 0.14 % of all tumo rs in the CPA .~Prior to the publication of this article, onl y 36 cases of IAC lipom a have been reported, mo st of them in whit es.? No case has eve r been reported of a patient with an IAC lipoma in addit ion to multiple lipomas over the trunk and limb s.
On histologic study, typic al IAC and CPA lipomas 342 contain mature adipose eelis and varying degrees offibrovascular tissue.' The adipose tissue thoroughly infiltrates and separates the involved nerv e fibers. These lesions are probably malformative rath er than neoplastic in nature. ' Lipomas usually grow extrem ely slowly, and no mali gnant transformation has been reported. If a patient with a definit e diagno sis exhibits no clinic al symptoms, con servative followup is some times the best option. Unlik e other intracranial lipomas, IAC and CPA lipomas can intimately involve the cranial ner ves and produce progressive focal symptoms. Acco rding to a study by Bigelow et al, the thre e most comm on symptoms of IAC and CPA lipomas are hearin g loss (in 64 % of patient s), dizziness (44%), and tinn itus (43%).2 The most frequently involv ed cranial ner ves are the auditory ner ve (98%), facial nerve (85%), and trigemin al nerve (24%).2Because these lesions are so infiltrative in natur e, it is sometimes diffi cult to preserve hearing durin g surge ry. When a total resection of the tumor is performed, it is usually undertaken via the tran slabyrinthine approach , in which hearing cannot be preserved. Becau se there is a high risk of TheIrequency and magnitude of laboratory abnormalities were simila r in texofenadine hydroehlorideand plaeebo-treatedpatients. Pedialrie. Table 2 lists adverse experie nces in patients aged6 to 11 years 01agewhich werereported by greater than2% 01patients treated with fexcfenadine hydroehloride tablets at a dose 0130 mg twice daily in plaeebo-eontrotled seasonal allergic rhinitis studies in the United Sta tes and Canada Ihat were more common with fexofenadine hydroeh lorideIhanplaceba. 
Adverse experience
Baek Pai n Sinusitis Di zziness Drowsiness DVERDDSAGE Reports of fexolenadine hydroehlori de overdose have been inlrequent a n~eontain limited information. However, dizziness, drowsiness, anddry mou th have been reported. Si ngledoses ot fexofenadme hydr oehJoride up to 800mg (six norrnaivolunteers at this doselevel), and doses upto 690 mgtwicedaily for 1 month (threenorrnai volunteers atthis doselevel) or 240mg onee dai ly for 1 year (234 normal volunteers at thiSdose level ) were administered without the development 01elinieally sigOlfieant adverse events aseomparedto placeba. In theeve nt ol overdase, eonside r standa rd measures to removeanyunabsorbeddrug. Symptomatieandsupporti vetreat ment is reeommended. Hemodialysis did not etfeetivel y remave fexo fenad ine hydroehloridelromblood (1.7% removed) following terfenadineadministration.
No deaths oeeurred at oral doses of fexo lenadinehydroehloride up to 5000 mglkg in miee (110 times the maximum reeommended dai ly oral dose in aduits and200timesthe maxim umreeommended dailyoraldosein childrenbased on mgl m l ) and up to 5000 mglkgin rats (230 timesthemaximum reeommended daily oral dosein aduits and400times the maximum reeomme nded daily aral dosein ehildrenbased~n mg/ml). Additionally, noelinieal signs01toxieity or grosspathologieallindings were observed. In dogs, no evidenee of toxielty wasobserved at oral dosesup to 2000mglkg (300times themaximum ree· ommende d daily oral dosein aduits and530 times themaximumreeommended daily aral dosein ehildrenbased on mg/m l ) .
Chron je Idjgoathjc Urtiearja
Adverseeve ntsreported by pati ents 12 years 01ageand 01der in plaeebo-controlled ehronie idiopathie urticariastudieswere similar to those reported in plaeebo-eontrolteci seasonal allergie rhinitis studies. In plaeebo-eontrolled ehronie idiopathie urticaria el inieal trials, whieh ineluded726patients 12 years of ageand older reeeiving lexofenadine hydroehloridetablets at doses of 20 to 240 mg ...../ieedai ly, adverse eve nts \'Iere similar in fexolenadinehydroeh lorideand plaeebo-treated pati ents. Table 3 lists adverse experienees in patients aged 12 yearsandolderwhieh were reported by grea ter than 2% 01 patients treated with fexofenadinehydroehloride 60 mg tablets twice daily in eontrolledeli nieal studies in theUnitedStates and Canada and thatwere mare common with fexo fenadine hydroehloride than placebo. The safety of fexolenadine hydroe hlori dein the.treatment 01chronie idiopathie urtiearia in pediatrie pati ents 6 to 11 years 01age is basedon the safety profile of lexolenadlOe hydroehloride in adulis andadoleseent patients at doses equal to or higher thanthe reeommended dose(seePediatric Use). The changes in plasma levels werewithi n the range of plasma levels aehieved inadequate and weli-eontrolled c!inieal trials. Themeehanism ofIheseinteractions hasbeenevaluatedin in vitro, in situ, andin vivoanimai madeIs. These studies indieale that kelocona zoleor erythromyeineo-administrationenhanees lexole nadine gastroinlestinal absorption. fn vivoanimal sludiesalsosuggest that in addit ion to inereasing absorption, ketoeonazole decreases fexofenadi ne hydroehloride gastrointestinal seerelion,whi le erythro· myein may alsodecrease bili ary exe reti on. Orug Inleraclions wilh Antae jds Administration of 120 mg 01fexolenadinehydroehloride(2x 60 mg eapsule) within 15 minutesof an aluminum and magnesium containing antaeid (Maalaxl) dee reased fexofenadineAUGby41% and Cm v:by 43%. ALLEG RAshouldnot betaken elosely in timewithal uminumand magnesiumcontai ning antaeids. Carejnogenesis Mulagenesis ImpairmenlofEerlBily Thecareinogen iepotential and reproductivetoxieityof fexofenadine hydroehloride were assessed using terlenadine studies wilh adequatefexolenadinehydroehl orideexposure (based on plasmaareaunder-the·eonee ntration vs. time (AU G] values). No evi den ee of ear einogenieity was observed in an 18-month study in mieeand in a 24-month studyin rats at oral doses upto 150 mg/kg of terfenadine (whieh led to fexofenadine exposures that were respeetively approximately 3 and 5 times Ihe exposureIrom the maximumreeommended daily oral dose 01lexole nadinehydroehl oride in aduUs andehi ldren). . In in vitro (Baeterial Reverse Mutation, GHOIHGP RT Eor ward Mutation, and Rat Lymphocyte Chromosomal Aberratlon assays) and in vivo(Mouse Bone MarrowMicronueleus assay)tesIs, fexofenadine hydroehloride revealed no evideneeof mutagenieity. In rat fertility studies,dose-related reduetions in implants and increases in postimpl antation losses were observed al an oral dose of 150 mglkg01terfenadine (whieh led to lexofenadine hydroehtoride exposures that wereapproximately3 times the exposure01Ihemaximumreeommended dai ly oral doseof fexofenadine hydroehloridein aduits).
TeratogeoieElfeets: CalegoryC. There wasno evidenee of teratogenieity in rats or rabbits at oral doses 01terfenadi neup to 300 mglkg (whieh ledla lexolenadine exposuresthat were approximately4 and 31 times, respeetivel y, the exposure Irom the maximum reeommend eddail y oral dose of fexofenadine in adults). There are no adequate andweil eonlrolled studiesin pregnant women . Eexolenadine should be usedduring pregnancy only if the potential benefit justifles the potential risk to the letus. Nooler atageoie Eff eels. Dose-relaleddecreases in pup weight gain andsurvi val were~bserve d in rats exposed~o anoral dose of 150 mglkgol terf ena dine(approximate ly 3 limesthemaximumreeommended daIly oraldose of fexolenadlOe hydroehloridein adulis based oncamparisan 01fexolenadinehydroehlorideAUCs). NursjngMolhers There areno adequate and well ·conlrolled studiesin women during lactation. Beeause manydrugs are exeretedin human milk, eaution shouldbe exereised when lexofenadinehydroehlorideis administeredto a nursing woman.
The reeommended dose in pati enls 6 to 11 years of age is based on eross-study camparisan of the p ha rm a e o k i ne t i~s of ALLEG RAin aduits andpediatrie paHents andon the saletyprofile 01fexolenadine hydroehloridein both adult and pedlatrie patients at doses equalto or higher than the reeommended doses. Thesafetyof ALLEG RAtablets at a doseof 30 mgtwice daily has been demonstrated in 438pediatric palients 6 to 11years 01agein two plaeebo-eontrolled 2-week sea sonalallergierhinitis trials. The safety of ALLEG RAfor the treat ment 01ehronie idiopathic urticaria in patients 6 to 11 years of ageis basedon eross-sludy compari son of thepharmaeokineties of ALLEG RA in adult and pediatrie pat ients andon the saletyprofile of lexofenadine in both adult and pedialrie patients at doses equal to or higherthan thereeommended dose. The elfeetiveness of ALLEGRA lor the treatment of seaso nal alte rgierhiniti s in patients 6 to 11 yearsof agewasdemonstraled in onetrial (n=411) in whieh ALLEG RAtablets30 mg twice dai ly signilieantlyredueed total symp tomseoreseom pared to placeba, along with extrapo lation of demonslrated elfieaey in pal ients ages 12 years and above, andthe pharmaeokinetie comparisonsin adui ts and ehildren. The effeel ivenessof ALLEGRA for thetreatment 01ehronic idiopathieurtieariain.patients 610 11 yea rs of ageis based onanextrapalatian of the demonstrated elfieaey of ALLEGR A in adults with this eon dltion and the likeH hood that the disea se eourse, pathophysiology and thedrug's elfeelare substantiall y similar in ehildren to that 01 adultpatients. The salety and etfeetiveness of ALLEGRA in pedialrie pat ientsunder 6 years 01age have not been establi shed. Cliniealstudies of ALLEGRA tab.lets and e a p s u ls did not inelude suffjeient numbers 01subjeets aged 65 ye a~s andover to determine whetherIhis populahon responds dltferently from younger patients. Other report ed ehnieal expenenee has not identilieddiffereneesin responses between thegeriatrieand younge r palients. This drug is known to besubstantiall y exe reted bythekidney, and the risk 01toxicreaetions to this drugmay begrealer in patients \'/ith impaired renal funetion. Beeause
Concomitant Drug
Erythromycin pos toperative neurologic seq uelae, surgica l interve ntion is indica ted only when the patient has significant progressive or disabl ing symptoms . Before proceed ing to surgery or deciding on no treatment , it is necessary to confirm the diagnosis with imaging studies. The characteris tic findings of lipom as on CT and MRI are weil desc ribed ." Fat is hypointense on CT, which is reflecte d by the neg ative Hounsfield units (usually -25 to -100). On MRI, fat is hyperintense on Tlweig hted images and hypointense-to-isointense on T2weig hted images . Gadolini um contrast offers no significant enhancement. Fat-suppression techn iques can be applied to MRI to suppress the strong signals fro m fatty tiss ue, which interfere wit h the signals fro m adjacent areas. Nowad ays, fat-suppression MRI is the best choice for diagnosing lipomas of the temp orai bone.'
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